Author’s Reply “Considerations Regarding a Cohort Study on Concomitant Use of Central Nervous System-Active Medications in Patients With COPD”

Sood A Kuo Y-F Westra J Sharma G Raji MA . Co-prescribing of central nervous system–active medications for COPD patients: Impact on emergency room visits and hospitalization. Ann Pharmacother. [published online ahead of print August 9, 2022]. doi:10.1177/10600280221113299

Cavalcante AN Sprung J Schroeder DR Weingarten TN . Multimodal analgesic therapy with gabapentin and its association with postoperative respiratory depression. Anesth Analg. 2017;125(1):141-146. doi:10.1213/ANE.0000000000001719.

Weingarten TN Jacob AK Njathi CW Wilson GA Sprung J . Multimodal analgesic protocol and postanesthesia respiratory depression during phase I recovery after total joint arthroplasty. Reg Anesth Pain Med. 2015;40(4):330-336. doi:10.1097/AAP.0000000000000257.

Overholser BR Foster DR . Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011;17(suppl 11):s276-s287.

Yunusa I Gagne JJ Yoshida K Bykov K . Risk of opioid overdose associated with concomitant use of oxycodone and selective serotonin reuptake inhibitors. JAMA Netw Open. 2022;5(2):e220194. doi:10.1001/jamanetworkopen.2022.0194.